Zif-A48 mg+0.5 mg+22.5 mg

Zif-A 48 mg+0.5 mg+22.5 mg is a combination hematinic and micronutrient supplement used for the following indications:

Established/Primary Use

• Prevention and treatment of iron-deficiency anemia, particularly in individuals whose diet is inadequate to meet increased iron, folic acid, and zinc requirements.
• Prophylaxis of iron, folic acid, and zinc deficiency during pregnancy and lactation, when dietary intake alone is insufficient.

Guideline-Supported / Adjunct Use

• As part of antenatal micronutrient supplementation programs in populations at risk of combined iron, folate, and zinc deficiency (consistent with WHO guidance on iron and folic acid supplementation in pregnancy).
• Correction of mild-to-moderate iron-deficiency anemia as an adjunct to dietary correction, in patients who tolerate oral iron poorly with other salts (ferrous ascorbate is generally better tolerated and better absorbed than some conventional iron salts).

Zif-A 48 mg+0.5 mg+22.5 mg is not intended for use in iron-overload states or in anemias not due to combined iron/folate/zinc deficiency.

Each dosage unit of Zif-A 48 mg+0.5 mg+22.5 mg typically contains:

• Ferrous Ascorbate - an iron compound providing elemental iron, combined with ascorbate to improve gastrointestinal tolerability and absorption compared with some other iron salts.
• Folic Acid - a synthetic form of vitamin B9, essential for red blood cell formation and fetal neural development.
• Zinc Sulfate (usually as the monohydrate) - provides elemental zinc, an essential trace mineral involved in immune function, wound healing, and cell division.

Exact strengths of ferrous ascorbate, folic acid, and zinc sulfate vary by manufacturer and product label; refer to the specific product packaging for the elemental iron/zinc content of a given brand of Zif-A 48 mg+0.5 mg+22.5 mg.

Zif-A 48 mg+0.5 mg+22.5 mg is a fixed-dose oral combination product formulated for the prevention and treatment of iron-deficiency anemia associated with concurrent folic acid and zinc insufficiency. It combines three complementary micronutrients:

• Ferrous ascorbate, an organic iron salt chosen for its relatively favorable gastrointestinal tolerability and bioavailability;
• Folic acid, which supports erythropoiesis (red blood cell production) and is important for fetal neural tube development during pregnancy; and
• Zinc sulfate, which supplies elemental zinc to support immune function and normal growth.

Zif-A 48 mg+0.5 mg+22.5 mg is widely used as an antenatal and general hematinic supplement in populations with combined micronutrient deficiencies, and is available in Bangladesh as an oral tablet/capsule formulation.

Zif-A 48 mg+0.5 mg+22.5 mg belongs to the therapeutic class of hematinic and micronutrient (iron, folic acid, and trace mineral) combination preparations, used for the management and prevention of nutritional anemia.

Zif-A 48 mg+0.5 mg+22.5 mg combines three agents with complementary mechanisms of action:

Ferrous Ascorbate

Provides elemental iron in a form combined with ascorbate (vitamin C), which enhances reduction of ferric iron to the more readily absorbed ferrous state in the gastrointestinal tract, improving absorption and reducing gastric irritation relative to some inorganic iron salts. Absorbed iron is incorporated into hemoglobin, myoglobin, and iron-dependent enzymes, correcting iron-deficiency anemia and replenishing iron stores.

Folic Acid

Folic acid is converted to its active metabolite, tetrahydrofolate, which is required for DNA synthesis and normal erythropoiesis. Supplementation corrects megaloblastic changes due to folate deficiency and supports the increased folate demand of pregnancy, including reduction of neural tube defect risk.

Zinc Sulfate

Zinc is an essential cofactor for numerous metalloenzymes involved in DNA and protein synthesis, immune function, and cell growth/division. Supplementation corrects zinc deficiency, which commonly coexists with iron deficiency in populations with inadequate dietary diversity.

Together, the components of Zif-A 48 mg+0.5 mg+22.5 mg address the overlapping nutritional deficiencies commonly seen in pregnancy and in populations with limited dietary micronutrient intake.

Zif-A 48 mg+0.5 mg+22.5 mg should be swallowed whole with a glass of water, preferably after meals to minimize gastrointestinal discomfort. It should not be taken at the same time as antacids, calcium or zinc-containing products, tetracyclines/fluoroquinolones, or levothyroxine; separate dosing by at least 2 hours from these agents.

Zif-A 48 mg+0.5 mg+22.5 mg has the following well-documented, clinically significant interactions:

• Tetracycline and fluoroquinolone antibiotics: Iron and zinc chelate with these antibiotics, substantially reducing absorption of both the antibiotic and the mineral. Separate administration by at least 2 hours.
• Levothyroxine: Iron and zinc can reduce absorption of levothyroxine, potentially reducing its efficacy. Separate dosing by at least 4 hours.
• Antacids and proton pump inhibitors/H2-blockers: Reduced gastric acidity impairs iron absorption from Zif-A 48 mg+0.5 mg+22.5 mg; separate dosing where possible.
• Penicillamine: Iron reduces absorption of penicillamine; separate administration if both are required.
• Calcium supplements or dairy products: May reduce absorption of the iron component of Zif-A 48 mg+0.5 mg+22.5 mg; avoid co-administration.

Patients should inform their physician of all concurrent medications before starting Zif-A 48 mg+0.5 mg+22.5 mg.

Side effects of Zif-A 48 mg+0.5 mg+22.5 mg are generally mild, dose-related, and transient, mostly related to the iron component:

• Nausea, epigastric pain, and heartburn
• Constipation or, less commonly, diarrhea
• Dark or black-colored stools (a harmless effect of unabsorbed iron)
• Metallic taste (occasionally related to zinc)
• Rarely, allergic reactions (rash, pruritus) related to folic acid or other components

Gastrointestinal side effects often improve by taking Zif-A 48 mg+0.5 mg+22.5 mg with food or by temporarily reducing the dose; persistent or severe symptoms should be reported to a physician.

Zif-A 48 mg+0.5 mg+22.5 mg is commonly used as an antenatal micronutrient supplement; however, use should be individualized. First-trimester use should generally be reserved for cases of confirmed iron/folate/zinc deficiency, as routine high-dose iron supplementation is not universally recommended in early pregnancy. From the second trimester onward, iron, folic acid, and zinc supplementation is well established as beneficial when dietary intake is inadequate.

Zif-A 48 mg+0.5 mg+22.5 mg should be used only if clearly needed, and the potential benefit is judged by a physician to justify any potential risk; pregnant women should consult their physician before starting or continuing Zif-A 48 mg+0.5 mg+22.5 mg.

Small amounts of iron, folic acid, and zinc are excreted in breast milk, but supplementation at recommended doses is generally considered compatible with breastfeeding. Lactating women should still consult their physician before use.

Use Zif-A 48 mg+0.5 mg+22.5 mg with caution in the following situations:

• Peptic ulcer disease or active gastrointestinal inflammation: the iron component may aggravate gastric irritation; monitor for worsening symptoms.
• Risk of iron overload: patients with a family history of hemochromatosis or other conditions predisposing to iron accumulation should be assessed before long-term use (see Contraindications).
• Masking of vitamin B12 deficiency: the folic acid component can correct the anemia and blood picture caused by vitamin B12 deficiency without correcting the underlying neurological effects; vitamin B12 status should be evaluated where clinically indicated before or during use of Zif-A 48 mg+0.5 mg+22.5 mg.
• Renal impairment: zinc accumulation is more likely in patients with reduced renal function; use with medical supervision.
• Keep out of reach of children; accidental overdose of iron-containing products is a recognized cause of pediatric poisoning (see Overdose).

If symptoms do not improve or if the underlying anemia does not respond to therapy, the patient should be re-evaluated for alternative causes of anemia.

Overdose of Zif-A 48 mg+0.5 mg+22.5 mg, particularly the iron component, can be serious, especially in children. Symptoms may include abdominal pain, nausea, vomiting, diarrhea, dark or tarry stools, vomiting of blood, low blood pressure, rapid heart rate, drowsiness, metabolic acidosis, and in severe cases, seizures, shock, or coma.

Suspected overdose of Zif-A 48 mg+0.5 mg+22.5 mg is a medical emergency: seek immediate medical attention or contact a poison control center/emergency services without delay. Do not attempt to manage a significant overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Safety and efficacy of Zif-A 48 mg+0.5 mg+22.5 mg as a fixed-dose combination have not been established in children; pediatric iron, folic acid, and zinc supplementation should generally use age-appropriate, weight-based single-agent formulations under medical supervision.

Elderly: No specific dose adjustment is generally required, but elderly patients may be more prone to gastrointestinal side effects and should be monitored.

Renal impairment: Use with caution due to potential zinc accumulation; medical supervision advised.

Hepatic impairment: No well-established dose adjustment is required, but caution is advised as with any iron-containing product in patients with liver disease and iron overload risk.

Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Zif-A 48 mg+0.5 mg+22.5 mg therapy should be individualized by a physician, typically continued for several weeks to months until hemoglobin normalizes and iron stores are replenished, and then often continued at a lower maintenance dose during pregnancy as advised by the treating physician. Treatment response should be monitored with periodic blood counts.

Zif-A 48 mg+0.5 mg+22.5 mg falls under the drug class of hematinics and micronutrient (iron, folic acid, and zinc) combination supplements.

Zif-A 48 mg+0.5 mg+22.5 mg acts by replenishing iron, folic acid, and zinc stores through oral supplementation: ferrous ascorbate supplies elemental iron for hemoglobin synthesis with enhanced absorption via its ascorbate component, folic acid supports DNA synthesis and red blood cell maturation, and zinc sulfate provides elemental zinc for numerous enzymatic and immune functions, together correcting combined micronutrient-deficiency anemia.

Safety and efficacy of Zif-A 48 mg+0.5 mg+22.5 mg have not been established in the pediatric population as a fixed-dose combination. When iron, folic acid, or zinc supplementation is required in children, physicians typically prescribe age- and weight-appropriate single-agent formulations rather than this adult combination product, and pediatric use of Zif-A 48 mg+0.5 mg+22.5 mg should only occur under direct medical supervision.